Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/hepatotoxicity-of-contemporary-antiretroviral-drugs-kn4I5bW803
References (57)
-
(2021)
Prescribing Information (USA). Titusville, NJ: Janssen Therapeutics -
Kenneth Mayer, J. Molina, Melanie Thompson, Peter Anderson, K. Mounzer, Joss Wet, E. Dejesus, H. Jessen, Robert Grant, Peter Ruane, Pamela Wong, R. Ebrahimi, Lijie Zhong, A. Mathias, C. Callebaut, Sean Collins, M. Das, S. McCallister, Diana Brainard, C. Brinson, A. Clarke, P. Coll, Frank Post, C. Hare (2020)
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialLancet (London, England), 396
-
C. Flexner (1998)
HIV-protease inhibitors.The New England journal of medicine, 338 18
-
D. Bentué‐Ferrer, C. Arvieux, O. Tribut, A. Ruffault, É. Bellissant (2009)
Clinical pharmacology, efficacy and safety of atazanavir: a reviewExpert Opinion on Drug Metabolism & Toxicology, 5
-
E. Mondou, J. Sorbel, J. Anderson, H. Momméja-Marin, A. Rigney, F. Rousseau (2005)
Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 41 5
-
S. Lim, T. Ng, N. Kung, Z. Krastev, M. Volfová, P. Husa, Samuel Lee, S. Chan, M. Shiffman, M. Washington, A. Rigney, Jane Anderson, E. Mondou, Andrea Snow, J. Sorbel, R. Guan, F. Rousseau (2006)
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.Archives of internal medicine, 166 1
-
(2019)
Long-term safety and efficacy of fostemsavir in treatment-experienced HIV participants -
R. Gish, H. Trinh, N. Leung, F. Chan, M. Fried, T. Wright, Chia Wang, Jane Anderson, E. Mondou, Andrea Snow, J. Sorbel, F. Rousseau, L. Corey (2005)
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.Journal of hepatology, 43 1
-
(2017)
Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial§Current HIV Research, 15
-
Margaret Johnson, Princy Kumar, J. Molina, G. Rizzardini, P. Cahn, M. Bickel, J. Mallolas, Yan Zhou, Cristiana Morais, Sushma Kumar, P. Sklar, G. Hanna, C. Hwang, W. Greaves (2019)
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT TrialJournal of Acquired Immune Deficiency Syndromes (1999), 81
-
C. Cohen, J. Andrade-Villanueva, B. Clotet, J. Fourie, M. Johnson, K. Ruxrungtham, Hao Wu, C. Zorrilla, H. Crauwels, L. Rimsky, S. Vanveggel, K. Boven (2011)
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 378
-
M. Sulkowski, D. Thomas, R. Chaisson, R. Moore (2000)
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.JAMA, 283 1
-
F. Mitsumoto, M. Murata, Y. Kato, K. Ura, Koji Takayama, Satoshi Hiramine, H. Ikezaki, Motohiro Shimizu, K. Toyoda, E. Ogawa, S. Aishima, N. Furusyo, J. Hayashi (2014)
Hepatitis B virus-related immune reconstitution inflammatory syndrome in two patients coinfected with human immunodeficiency virus diagnosed with a liver biopsy.Internal medicine, 53 18
-
(2020)
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV -
(2019)
The occurrence of hypersensitivity reaction and hepatotoxicity in individuals receiving integrase strand transfer inhibitors : Results from the EuroSIDA study -
M. Kozal, J. Aberg, G. Pialoux, P. Cahn, M. Thompson, J. Molina, B. Grinsztejn, R. Diaz, A. Castagna, Princy Kumar, G. Latiff, E. Dejesus, Mark Gummel, M. Gartland, A. Pierce, Peter Ackerman, C. Llamoso, Pablo Belaunzarán-Zamudio (2020)
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.The New England journal of medicine, 382 13
-
N. Yancheva, R. Tzonev (2019)
A case of late presentation of darunavir-related cholestatic hepatitisInternational Journal of STD & AIDS, 30
-
FDA summary letter: Ibalizumab. FDA -
Bo Wang, L. Abbott, K. Childs, Chris Taylor, K. Agarwal, I. Cormack, R. Miquel, A. Suddle (2018)
Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literatureInternational Journal of STD & AIDS, 29
-
P. Sax, A. Pozniak, Luisa Montes, E. Koenig, E. Dejesus, H. Stellbrink, A. Antinori, K. Workowski, J. Slim, J. Reynes, W. Garner, J. Custodio, K. White, Devi SenGupta, A. Cheng, E. Quirk (2017)
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialThe Lancet, 390
-
A comparison of the safety and efficacy of the latest generation nonnucleoside reverse transcriptase inhibitors (NNRTI) with the flag bearer of the class -
J. Casado, A. Mena, S. Bañón, Á. Castro, C. Quereda, A. Moreno, J. Pedreira, S. Moreno (2016)
Liver toxicity and risk of discontinuation in HIV/hepatitis C virus‐coinfected patients receiving an etravirine‐containing antiretroviral regimen: influence of liver fibrosisHIV Medicine, 17
-
(2019)
Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals (Abstract 485). CROI -
L. Taramasso, P. Lorenzini, A. Biagio, M. Lichtner, G. Marchetti, R. Rossotti, G. Lapadula, A. Cozzi-Lepri, F. Vichi, A. Antinori, S. Bonora, A. Monforte (2019)
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.The Journal of antimicrobial chemotherapy
-
F. Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, P. Cahn, U. Lalloo, IP Westhuizen, Malan, Margaret Johnson, B. Santos, F. Mulcahy, R. Wood, GC Levi, G. Reboredo, K. Squires, I. Cassetti, D. Petit, F. Raffi, C. Katlama, R. Murphy, A. Horban, JP Dam, E. Hassink, R. Leeuwen, P. Robinson, F. Wit, J. Lange (2004)
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyThe Lancet, 363
-
Princeton, NJ: Bristol-Myers Squibb Company -
D. Dieterich (2003)
Managing anti‐retroviral‐Associated Liver DiseaseJAIDS Journal of Acquired Immune Deficiency Syndromes, 34
-
M. Nelson, G. Amaya, N. Clumeck, C. Cunha, D. Jayaweera, P. Junod, Taisheng Li, P. Tebas, M. Stevens, A. Buelens, S. Vanveggel, K. Boven (2012)
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.The Journal of antimicrobial chemotherapy, 67 8
-
Week-144 results from double-blind, active-controlled studies, exploring intra class efficacy and safety differences between two INSTIs -
B. Emu, E. Dejesus, M. Berhe, J. Leider, C. Creticos, S. Weinheimer, Z. Cohen (2019)
661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)Open Forum Infectious Diseases, 6
-
S. Tsiodras, C. Mantzoros, C. Mantzoros, S. Hammer, M. Samore (2000)
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.Archives of internal medicine, 160 13
-
C. Orkin, K. Squires, J. Molina, P. Sax, O. Sussmann, G. Lin, Sushma Kumar, G. Hanna, C. Hwang, E. Martin, H. Teppler (2020)
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority TrialClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73
-
P. Sax, E. Dejesus, G. Crofoot, D. Ward, P. Benson, R. Dretler, A. Mills, C. Brinson, J. Peloquin, Xuelian Wei, K. White, A. Cheng, Hal Martin, E. Quirk (2017)
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.The lancet. HIV, 4 4
-
M. Nunez (2006)
Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.Journal of hepatology, 44 1 Suppl
-
Erin Christensen, R. Jain, A. Roxby (2017)
Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected PatientOpen Forum Infectious Diseases, 4
-
M. Lataillade, J. Lalezari, M. Kozal, J. Aberg, G. Pialoux, P. Cahn, M. Thompson, J. Molina, S. Moreno, B. Grinsztejn, R. Diaz, A. Castagna, Princy Kumar, G. Latiff, Edwin Jesus, Marcia Wang, Shiven Chabria, M. Gartland, A. Pierce, Peter Ackerman, C. Llamoso (2020)
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.The lancet. HIV, 7 11
-
Fengxiang Qin, Junjun Jiang, C. Qin, Yunxuan Huang, B. Liang, Yuexiang Xu, Jiegang Huang, Zhiliang Xu, C. Ning, Yanyan Liao, N. Zang, Jingzhen Lai, Wudi Wei, Jun Yu, Lijing Ye, Xionglin Qin, Hao Liang (2019)
Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: an 11-year retrospective cohort study in Guangxi, ChinaBMJ Open, 9
-
(2010)
Hepatic safety and tolerability in the maraviroc clinical development program -
Research Triangle Park, NC: ViiV Healthcare; Revised -
B. Emu, J. Fessel, S. Schrader, Princy Kumar, G. Richmond, Sandra Win, S. Weinheimer, C. Marsolais, S. Lewis (2018)
Phase 3 Study of Ibalizumab for Multidrug‐Resistant HIV‐1The New England Journal of Medicine, 379
-
S. Rizza, R. Bhatia, J. Zeuli, Z. Temesgen (2019)
Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.Drugs of today, 55 1
-
Salin Nhean, D. Yoong, D. Wong, Kevin Gough, A. Tseng (2019)
Probable hepatotoxicity with dolutegravir: report of two cases and review of the literature.AIDS
-
P. Bagella, G. Socio, E. Ricci, B. Menzaghi, C. Martinelli, N. Squillace, P. Maggi, G. Orofino, L. Calza, L. Carenzi, B. Celesia, G. Penco, A. Biagio, L. Valsecchi, F. Vichi, Valeria Colombo, G. Parruti, C. Dentone, K. Falasca, P. Bonfanti, G. Madeddu (2018)
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA ProjectInfection and Drug Resistance, 11
-
M. Sulkowski (2008)
Management of hepatic complications in HIV-infected persons.The Journal of infectious diseases, 197 Suppl 3
-
M. Sulkowski (2004)
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 38 Suppl 2
-
C. Orkin, E. Dejesus, P. Sax, J. Arribas, Samir Gupta, C. Martorell, J. Stephens, H. Stellbrink, D. Wohl, F. Maggiolo, M. Thompson, D. Podzamczer, D. Hagins, J. Flamm, C. Brinson, A. Clarke, Hailin Huang, Rima Acosta, D. Brainard, Sean Collins, Hal Martin (2020)
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.The lancet. HIV, 7 6
-
M. Thompson, J. Lalezari, R. Kaplan, Y. Pinedo, Otto Pena, P. Cahn, D. Stock, Samit Joshi, G. Hanna, M. Lataillade (2017)
Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled TrialAntiviral Therapy, 22
-
N. Terrault, A. Lok, B. McMahon, Kyong‐Mi Chang, J. Hwang, M. Jonas, Robert Brown, N. Bzowej, J. Wong (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 67
-
David Schlossberg, Rafik Samuel (2017)
PREZCOBIX (Darunavir + Cobicistat) -
S. Soni, D. Churchill, Y. Gilleece (2008)
Abacavir-induced hepatotoxicity: a report of two cases.AIDS, 22 18
-
(2018)
FDA summary letter: Ibalizumab -
B. Alejos, I. Suárez-García, M. Rava, Azucena Bautista-Hernández, F. Gutiérrez, D. Dalmau, I. Sagastagoitia, A. Rivero, S. Moreno, I. Jarrín, S. Moreno, I. Jarrín, D. Dalmau, M. Navarro, M. González, Federico García, E. Poveda, J. Iribarren, F. Gutiérrez, R. Rubio, F. Vidal, J. Berenguer, Juan González, M. Muñoz‐Fernández, I. Jarrín, B. Alejos, Cristina Moreno, C. Iniesta, Luis Sousa, Nieves Perez, M. Rava, I. Fernández, E. Merino, G. García, I. Portilla, I. Agea, J. Portilla, J. Sánchez-Payá, J. Rodríguez, L. Gimeno, L. Giner, M. Díez, M. Carreres, S. Reus, V. Boix, D. Torrús, A. Lirola, Dácil García, Felicitas Díaz-Flores, J. Gómez, M. Alonso, R. Pelazas, J. Hernández, M. Alemán, María Espersson, V. Asensi, E. Valle, M. Carmenado, Tomás Secades, L. Pérez, F. Pulido, O. Bisbal, A. Hernando, L. Domínguez, D. Crestelo, L. Bermejo, Mireia Santacreu, J. Iribarren, J. Arrizabalaga, M. Aramburu, X. Camino, F. Rodríguez-Arrondo, M. Wichmann, L. Tomé, M. Goenaga, Ma Bustinduy, Harkaitz Azkune, M. Ibarguren, A. Lizardi, X. Kortajarena, Ma Oyaga, M. Igartua, M. Masiá, S. Padilla, Catalina Robledano, Joan Colomé, Araceli Adsuar, R. Pascual, Marta Fernández, J. García, X. Barber, Vanessa Re, Javier Abellán, Reyes Pérez, María Roca, R. Muga, A. Sanvisens, D. Fuster, J. Quirós, I. Gutiérrez, M. Ramírez, B. Padilla, P. Gijón, T. Aldámiz‐Echevarría, F. Tejerina, F. Parras, P. Balsalobre, C. Díez, Leire Latorre, C. Fanciulli, J. Peraire, C. Viladés, S. Veloso, M. Vargas, M. Olona, A. Rull, E. Rodríguez-Gallego, V. Alba, Alfonso Castellanos, M. López-Dupla, M. Alonso, J. Aldeguer, Marino Juliá, M. Pitarch, Iván Hernández, Eva Muñoz, S. Tovar, M. Lletí, J. Navarro, J. González-García, F. Arnalich, J. Arribas, Jose Serna, J. Castro, A. Hierro, L. Escosa, P. Herranz, V. Hontañón, S. García-Bujalance, Milagros López-Hortelano, A. González-Baeza, M. Martín-Carbonero, M. Mayoral, M. Mellado, R. Micán, R. Montejano, M. Montes, V. Moreno, I. Pérez-Valero, G. Cebrián, B. Rodés, T. Sainz, E. Sendagorta, Natalia Alcáriz, E. Valencia, J. Blanco, J. Oteo, V. Ibarra, L. Metola, M. Sanz, L. Pérez-Martínez, P. Arazo, G. Sampériz, À. Jaén, M. Sanmartí, M. Cairó, J. Martínez‐Lacasa, Pablo Velli, R. Font, Miguel Martínez, F. Aiello, M. Marcotegui, J. Repáraz, M. Alda, María Cano, Beatriz Galarreta, M. Amengual, G. Navarro, M. Garcia, S. Isbert, M. Vilasaró, I. Santos, J. Sanz, A. Aparicio, C. Cepeda, L. Fraile, E. Gayo, J. Osorio, F. Núñez, A. Zamora, M. Elías, C. Gutiérrez, N. Madrid, S. Terrón, Sergio Villar, María Gallego, Javier Sanz, Usua Urroz, Tamara Velasco, E. Bernal, Alfredo Sánchez, Antonia García, Joaquín Urbieta, Á. Pérez, M. Alcaraz, Maria Villalba, Federico García, J. Quero, L. Medina, M. Álvarez, N. Chueca, D. García, Clara Martinez-Montes, Carlos Beltrán, Adolfo SalazarGonzalez, A. López, J. Romero, M. Utrilla, C. Rodríguez, T. Puerta, J. Carrió, M. Vera, J. Ballesteros, Oskar Ayerdi, A. Antela, E. Losada, M. Riera, M. Peñaranda, M. Ribas, A. Campins, C. Vidal, F. Fanjul, J. Murillas, Francisco Homar, H. Vilchez, M. Martín, A. Payeras, Jesús Santos, Cristina Ayerbe, I. Viciana, R. Palacios, C. López, Carmen Gonzalez-Domenec, P. Viciana, N. Espinosa, L. López-Cortés, D. Podzamczer, A. Imaz, J. Tiraboschi, A. Silva, M. Saumoy, P. Prieto, E. Ribera, A. Curran, J. Sierra, J. Stachowski, A. Arco, J. Torre, J. Prada, José Guerrero, O. Martínez, F. Vera, L. Martínez, Josefina García, B. Alcaraz, A. Jimeno, Á. Iglesias, Berta Souto, Álvaro Cea, J. Muñoz, M. Zubero, J. Baraia-Etxaburu, Sofía Ugarte, O. Benéitez, Josefina Munain, Ma López, M. Peña, Miriam López, Iñigo Azkarreta, C. Galera, H. Albendín, Aurora Pérez, A. Iborra, Antonio Vallecillo, M. Merlos, A. Vidal, M. Meca, C. Amador, F. Pasquau, J. Ena, C. Benito, Vicenta Fenoll, C. Anguita, José Rabasa, I. Suárez-García, E. Malmierca, P. González-Ruano, D. Rodrigo, Ma Seco, M. Mohamed-Balghata, M. Vidal, Miguel Zárraga, V. Pérez, M. Molina, Jorge García, Juncal Moreno, M. Górgolas, A. Cabello, B. Álvarez, Laura Prieto, J. Moreno, Alberto Caso, C. Gutiérrez, María Mena, M. Puerto, R. Vilalta, A. Ribera, A. Román, A. Juárez, P. López, I. Sánchez, Mario Casas, A. Espejo, M. Jiménez, R. Perea, J. Pineda, P. Mayo, Juan Sanchez, N. Gutierrez, L. Real, Ana Gómez, M. Fuertes, A. Gonzalez-Serna, Alexandre Pérez, M. Crespo, L. Morano, C. Miralles, A. Ocampo, Guillermo Pousada (2020)
Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.The Journal of antimicrobial chemotherapy
-
W. Towner, E. Dejesus, S. Schrader, Jerome Vente, C. McGary, Mohammed Zogheib, S. Weinheimer, P. Mesquita (2020)
1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 ParticipantsOpen Forum Infectious Diseases, 7
-
J. Gallant, A. Lazzarin, A. Mills, C. Orkin, D. Podzamczer, P. Tebas, P. Girard, I. Brar, E. Daar, D. Wohl, J. Rockstroh, Xuelian Wei, J. Custodio, K. White, Hal Martin, A. Cheng, E. Quirk (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialThe Lancet, 390
-
(2020)
The occurrence of hypersensitivity reaction and hepatotoxicity in individuals receiving integrase strand transfer inhibitors: Results from the EuroSIDA study. Centre of Excellence for Health, Immunity and Infections (CHIP) -
G. Rizzardini, E. Overton, C. Orkin, S. Swindells, K. Arastéh, M. Hernández-Mora, V. Pokrovsky, P. Girard, S. Oka, J. Andrade-Villanueva, G. Richmond, A. Baumgarten, M. Masiá, G. Latiff, Sandy Griffith, Conn Harrington, Krischan Hudson, M. Clair, C. Talarico, P. Patel, A. Cutrell, V. Eygen, R. D'Amico, J. Mrus, Sterling Wu, S. Ford, Ken Chow, Jeremy Roberts, Angela Wills, Nicola Walters, S. Vanveggel, R. Solingen-Ristea, H. Crauwels, Kimberly Smith, W. Spreen, D. Margolis (2020)
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsJournal of Acquired Immune Deficiency Syndromes (1999), 85
-
J. Molina, K. Squires, P. Sax, P. Cahn, J. Lombaard, E. Dejesus, M. Lai, A. Rodgers, L. Lupinacci, Sushma Kumar, P. Sklar, G. Hanna, C. Hwang, E. Martin (2019)
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.The lancet. HIV
- Publisher
- Wolters Kluwer Health
- Copyright
- Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
- ISSN
- 1746-630X
- eISSN
- 1746-6318
- DOI
- 10.1097/coh.0000000000000706
- Publisher site
- See Article on Publisher Site
Abstract
Purpose of reviewTo date, more than 30 antiretroviral drugs have been approved by the Food and Drug Administration for the treatment of HIV infection. As new drugs with better efficacy and safety profile become available for clinical practice, older drugs are either withdrawn from the market or become no longer actively prescribed. We review hepatotoxicity associated with contemporary antiretroviral drugs, with emphasis on data from the past 3 years.Recent findingsAlthough less robust data exists for side effects of contemporary antiretroviral medications recently approved for the management of HIV (i.e., doravirine, ibalizumab, fostemsavir, cabotegravir), the risks of substantial hepatotoxicity appears to be minimal with these agents.SummaryAlthough newer antiretroviral drugs are better tolerated than their earlier counterparts, they are not completely devoid of adverse drug reactions, including hepatotoxicity. Monitoring patients on antiretroviral therapy for treatment-emergent liver injury should continue to be part of routine clinical care.
Journal
Current Opinion in HIV and AIDS – Wolters Kluwer Health
Published: Nov 20, 2021